Browsing Tag
Radium Capital
2 posts
Acrux (ASX: ACR) secures clearer FDA Phase III pathway for female testosterone treatment
Acrux has received formal FDA feedback defining the Phase III clinical development requirements for Female Testosterone MDTS, potentially supporting a future United States registration application while leaving trial funding, safety evidence and commercial partnerships unresolved.
InFocus Group bets on Codexa as ASX: IFG looks for a sharper commercial reset
InFocus has Codexa ambition and Thai software traction. The harder test is whether ASX: IFG can convert both into cash discipline.